A case of clopidogrel induced neutropenia / 대한내과학회지
Korean Journal of Medicine
;
: 426-430, 2006.
Article
Dans Coréen
| WPRIM
| ID: wpr-208842
ABSTRACT
Clopidogrel is an oral agent that blocks ADP receptor-mediated platelet aggregation. Clopidogrel along with aspirin was shown by the CURE trial to result in a 20% relative reduction of cardiovascular death, myocardial infarction or stroke. Ticlopidine has been shown to reduce the incidence of stent thrombosis compared with warfarin, but it may cause serious hematological side effects. However, the reported neutropenia has been similar to clopidogrel and aspirin treatment groups (0.01 vs 0.17%, respectively) with corresponding rates (0.05 vs 0.04%, respectively) of severe neutropenia. We treated a 72-year-old female patient with severe neutropenia who underwent percutaneous coronary intervention with drug-eluting stent placement and had no neutrophils in the peripheral blood at 11 days after clopidogrel use. Therefore, clinicians should be alerted to the possibility of severe neutropenia with clopidogrel treatment.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Thrombose
/
Warfarine
/
Ticlopidine
/
Endoprothèses
/
ADP
/
Agrégation plaquettaire
/
Acide acétylsalicylique
/
Incidence
/
Accident vasculaire cérébral
/
Endoprothèses à élution de substances
Type d'étude:
Etude d'incidence
/
Étude pronostique
Limites du sujet:
Adulte très âgé
/
Femelle
/
Humains
langue:
Coréen
Texte intégral:
Korean Journal of Medicine
Année:
2006
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS